The Federal Trade Commission (FTC) announced on July 13, 2026, that it imposed penalties, totaling $12 million, in a failure-to-file settlement with Edwards Lifesciences Corp. and Genesis MedTech Group Limited.
The FTC complaint alleges that the companies violated the Hart-Scott-Rodino Act (HSR Act) when they closed an acquisition in July 2024 without submission of the required premerger notification and observation of the required waiting period.
The HSR Act requires parties of a certain size, contemplating transactions of a certain size, to notify both the FTC and the Department of Justice, Antitrust Division, and observe a waiting period (typically thirty days) before consummation.
Acquisitions of nonvoting securities are generally not reportable, and the value of nonvoting securities would not be included in the size-of-transaction threshold under the HSR Act.
The FTC alleges that the companies intentionally structured Genesis MedTech‘s sale of its subsidiary to Edwards to avoid triggering a filing.
Specifically, the FTC claims that Genesis MedTech would not accept a valuation below the then-applicable HSR threshold of $119.5 million, and alleges that Edwards did not want agency review to delay the transaction.
The buyer contemporaneously purchased $25 million of Genesis nonvoting securities in order to reduce the valuation of the voting securities to below the HSR Act‘s threshold.
They imposed penalties as a result of the companies’ actions.
The settlement includes penalties totaling $12 million.
It is a penalty for failure to file.
The companies must pay the penalties.
The FTC announced the settlement on July 13, 2026.
The settlement is related to the human needs that Edwards Lifesciences Corp. and Genesis MedTech Group Limited serve through their business operations.
The FTC settlement with Edwards Lifesciences Corp. and Genesis MedTech Group Limited is an example of the commission’s efforts to enforce the Hart-Scott-Rodino Act.
The Hart-Scott-Rodino Act is a law that requires companies to notify the government before making large acquisitions.
The government reviews these acquisitions to ensure they do not harm competition.
In this case, the FTC alleged that Edwards Lifesciences Corp. and Genesis MedTech Group Limited structured their deal to avoid this review.
The companies’ actions were a deliberate attempt to avoid the law.
The FTC took action against them as a result.
The penalties imposed on the companies are a significant amount.
The settlement is a reminder that companies must comply with the law.
The law is in place to protect competition and consumers.
Companies that violate the law will face penalties.
The FTC will continue to enforce the Hart-Scott-Rodino Act.
The commission’s actions will help to maintain a fair and competitive market.
Consumers will benefit from the FTC‘s efforts to enforce the law.
The settlement with Edwards Lifesciences Corp. and Genesis MedTech Group Limited is an important step in this process.
It demonstrates the FTC‘s commitment to enforcing the Hart-Scott-Rodino Act.
The commission’s work will help to promote competition and protect consumers.
Companies must take note of the FTC‘s actions and comply with the law.
Failure to do so will result in penalties.
The FTC will continue to monitor companies’ actions and take enforcement action when necessary.
Its efforts will help to create a fair and competitive market.
The market will benefit from the FTC‘s work.
Consumers will have more choices and better prices.
Companies will be able to compete fairly.
The FTC‘s enforcement of the Hart-Scott-Rodino Act is essential to maintaining a fair market.
It is a key part of the commission’s work.
The FTC will continue to enforce the law and protect consumers.
They will take action against companies that violate the law.
The settlement with Edwards Lifesciences Corp. and Genesis MedTech Group Limited is an example of the FTC‘s efforts.
It demonstrates the commission’s commitment to enforcing the Hart-Scott-Rodino Act and protecting consumers.
Leave a Reply